EA201401347A1 - Режимы дозирования антипрогестинов - Google Patents

Режимы дозирования антипрогестинов

Info

Publication number
EA201401347A1
EA201401347A1 EA201401347A EA201401347A EA201401347A1 EA 201401347 A1 EA201401347 A1 EA 201401347A1 EA 201401347 A EA201401347 A EA 201401347A EA 201401347 A EA201401347 A EA 201401347A EA 201401347 A1 EA201401347 A1 EA 201401347A1
Authority
EA
Eurasian Patent Office
Prior art keywords
estrogen
antiprogestines
endometriosis
treatment
present
Prior art date
Application number
EA201401347A
Other languages
English (en)
Other versions
EA032646B1 (ru
Inventor
Джозеф С. Подольски
Original Assignee
Репрос Терапьютикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Репрос Терапьютикс Инк. filed Critical Репрос Терапьютикс Инк.
Publication of EA201401347A1 publication Critical patent/EA201401347A1/ru
Publication of EA032646B1 publication Critical patent/EA032646B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Настоящее изобретение относится к способам введения композиций, включающих в себя антагониста рецепторов прогестерона, для применения при лечении эстроген-зависимых состояний. Изобретение также указывает на способы лечения болей, связанных с эндометриозом. Композиции могут вводиться женщинам, больным эндометриозом, а также женщинам, проходящим лечение эстрогеном и/или селективными модуляторами рецепторов эстрогена (СМРЭ). В некоторых вариантах осуществления настоящее изобретение представляет способ для подавления эндометриального разрастания.
EA201401347A 2008-04-28 2009-04-27 Режимы дозирования антипрогестинов EA032646B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4847208P 2008-04-28 2008-04-28

Publications (2)

Publication Number Publication Date
EA201401347A1 true EA201401347A1 (ru) 2015-07-30
EA032646B1 EA032646B1 (ru) 2019-06-28

Family

ID=40751037

Family Applications (3)

Application Number Title Priority Date Filing Date
EA201071249A EA201071249A1 (ru) 2008-04-28 2009-04-27 Режимы дозирования антипрогестинов
EA201401347A EA032646B1 (ru) 2008-04-28 2009-04-27 Режимы дозирования антипрогестинов
EA201990835A EA201990835A3 (ru) 2008-04-28 2009-04-27 Режимы дозирования антипрогестинов

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201071249A EA201071249A1 (ru) 2008-04-28 2009-04-27 Режимы дозирования антипрогестинов

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201990835A EA201990835A3 (ru) 2008-04-28 2009-04-27 Режимы дозирования антипрогестинов

Country Status (24)

Country Link
US (2) US8426394B2 (ru)
EP (1) EP2293797B1 (ru)
JP (1) JP5791499B2 (ru)
KR (2) KR20130059442A (ru)
CN (2) CN105616427A (ru)
AR (1) AR071516A1 (ru)
AU (1) AU2009241355B2 (ru)
BR (1) BRPI0911563A2 (ru)
CA (1) CA2722753C (ru)
CL (1) CL2009001010A1 (ru)
DK (1) DK2293797T3 (ru)
EA (3) EA201071249A1 (ru)
ES (1) ES2561810T3 (ru)
IL (1) IL208844A0 (ru)
ME (1) ME01123B (ru)
MX (1) MX2010011272A (ru)
MY (1) MY161059A (ru)
NI (1) NI201000183A (ru)
NZ (1) NZ589533A (ru)
SG (1) SG10201408483QA (ru)
TW (1) TWI477276B (ru)
UA (1) UA102849C2 (ru)
WO (1) WO2009134718A1 (ru)
ZA (1) ZA201007529B (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
HUP0900487A2 (hu) * 2009-08-05 2011-03-28 Richter Gedeon Nyrt 17-acetoxi-11ß-[4-(dimetil-amino)-fenil]-21-metoxi-19-norpregna-4,9-dién-3,20-dion új kristályos polimorf módosulata és eljárás elõállítására
UA113283C2 (xx) * 2010-12-23 2017-01-10 19-норстероїди і їх застосування для лікування прогестеронзалежних станів
EP2471537A1 (en) * 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
EP2854763B1 (en) * 2012-05-31 2018-09-26 Repros Therapeutics Inc. Formulations for vaginal delivery of antiprogestins
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP6343619B2 (ja) * 2012-11-02 2018-06-13 レプロス セラピューティクス インコーポレイティド プロゲステロン依存性病態を処置する方法およびその組成物
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
HU230381B1 (hu) * 2014-02-17 2016-03-29 Richter Gedeon Nyrt Ipari eljárás szteroid intermedier előállítására
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
EP3174542A4 (en) 2014-07-29 2018-01-03 TherapeuticsMD, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377418A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
ATE151286T1 (de) 1983-11-14 1997-04-15 Columbia Lab Inc Bioadhäsive mittel
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5439913A (en) * 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5468741A (en) 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
PL178174B1 (pl) * 1993-11-16 2000-03-31 Garfield Robert E Kompozycje farmaceutyczne do hamowania kurczliwości macicy lub stymulowania kurczliwości macicy
DE4426601A1 (de) * 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
SK282570B6 (sk) * 1995-02-02 2002-10-08 Schering Aktiengesellschaft Antagonisty progesterónu na výrobu liekov na ošetrenie dysfunkčného maternicového krvácania
DE69702450T2 (de) * 1996-05-01 2001-03-08 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer 21-substituierte progesteron derivate als antigestagene
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
AU2805397A (en) 1996-08-30 1998-03-19 Population Council, Center For Biomedical Research, The Vaginal application mifepristone
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6172052B1 (en) 1998-12-04 2001-01-09 Research Triangle Institute 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
EP1008443A1 (de) 1998-12-08 2000-06-14 Alusuisse Technology & Management AG Sterilisierbarer Folienverbund für Verpackungszwecke
US6740645B1 (en) 1999-09-03 2004-05-25 Research Triangle Institute 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties
DK1265911T3 (da) * 2000-03-17 2008-09-29 Us Gov Health & Human Serv 17-alfa-substitueret-11-beta-substitueret-4-aryl og 21-substitueret 19-norpregnadiendion som antiprogestationelle midler
IN191020B (ru) * 2000-03-28 2003-09-13 Dabur Res Foundation
CA2405500C (en) 2000-04-03 2006-08-22 Astenjohnson, Inc. Pre-crimped tie components
US7378406B2 (en) * 2000-10-18 2008-05-27 Schering Ag Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
DE60228583D1 (de) 2001-07-09 2008-10-09 Repros Therapeutics Inc Verfahren und materialien für die behandlung des testosteron-mangels bei männern
US7833545B2 (en) 2003-04-29 2010-11-16 The General Hospital Corporation Methods and devices for the sustained release of multiple drugs
EP1593376A1 (en) 2004-05-04 2005-11-09 Warner-Lambert Company LLC Improved pullulan capsules
AU2005265357B2 (en) * 2004-07-09 2011-04-07 Laboratoire Hra Pharma Sustained release compositions containing progesterone receptor modulators
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
DE102005028970A1 (de) * 2005-06-22 2006-12-28 Siemens Ag Piezoakter mit gesteigertem Hubvermögen
DE102005030294A1 (de) 2005-06-24 2007-01-04 Schering Ag Nichtsteroidale Progesteronrezeptor-Modulatoren
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
ES2643318T3 (es) 2006-10-24 2017-11-22 Repros Therapeutics Inc. Composiciones y métodos para suprimir la proliferación endometrial
EP2125858A2 (en) * 2007-01-17 2009-12-02 Repros Therapeutics Inc. Pharmaceutically acceptable salts of 11-(4-aminophenyl)-19-norpregna-4,9(10)-diene-3,20-dione derivatives
CA2682752C (en) 2007-04-05 2015-07-07 University Of Kansas Rapidly dissolving pharmaceutical compositions comprising pullulan
HRP20160689T1 (hr) * 2007-04-20 2016-07-15 Preglem S.A. Selektivni modulatori progesterona za tretman uterinog krvarenja
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
JP5992330B2 (ja) 2009-09-29 2016-09-14 メディメトリクス ペルソナリズド ドルグ デリヴェリー ベー ヴェ 物質を投与するための子宮内電子カプセル

Also Published As

Publication number Publication date
EP2293797A1 (en) 2011-03-16
WO2009134718A1 (en) 2009-11-05
IL208844A0 (en) 2011-01-31
NI201000183A (es) 2012-06-06
WO2009134718A8 (en) 2010-09-23
EA032646B1 (ru) 2019-06-28
US8735381B2 (en) 2014-05-27
BRPI0911563A2 (pt) 2016-07-12
EP2293797B1 (en) 2015-11-11
KR20130059442A (ko) 2013-06-05
JP5791499B2 (ja) 2015-10-07
SG10201408483QA (en) 2015-02-27
CA2722753A1 (en) 2009-11-05
US20110046098A1 (en) 2011-02-24
MX2010011272A (es) 2010-12-21
EA201071249A1 (ru) 2011-08-30
TW200950786A (en) 2009-12-16
ZA201007529B (en) 2011-07-27
ME01123B (me) 2013-03-20
ES2561810T3 (es) 2016-03-01
JP2011518845A (ja) 2011-06-30
EA201990835A3 (ru) 2019-12-30
CN102014923A (zh) 2011-04-13
KR20110014162A (ko) 2011-02-10
CA2722753C (en) 2018-07-03
EA201990835A2 (ru) 2019-08-30
TWI477276B (zh) 2015-03-21
US20130289008A1 (en) 2013-10-31
AU2009241355A1 (en) 2009-11-05
AR071516A1 (es) 2010-06-23
NZ589533A (en) 2012-06-29
CL2009001010A1 (es) 2009-06-19
DK2293797T3 (en) 2016-01-11
CN105616427A (zh) 2016-06-01
UA102849C2 (ru) 2013-08-27
US8426394B2 (en) 2013-04-23
MY161059A (en) 2017-04-14
AU2009241355B2 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
EA201071249A1 (ru) Режимы дозирования антипрогестинов
EA200970409A1 (ru) Композиции и способы, предназначенные для подавления эндометриальной пролиферации
EA201071250A1 (ru) Композиции и методы для лечения рака молочной железы
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
PE20090227A1 (es) Composiciones farmaceuticas que comprenden agentes anti-beta-klotho
EA201071169A1 (ru) ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3
DE602007010781D1 (de) N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid-derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration
EA200970835A1 (ru) Индазолы, применяемые для лечения расстройств, опосредуемых эстрогеновым рецептором бета
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
EA201490746A2 (ru) Применение прогестерона при профилактике и после острого периода для улучшения исходов, связанных с сотрясением мозга
MX2010004281A (es) Composiciones y metodos para el tratamiento de la retinopatia diabetica.
GB201201314D0 (en) Composition
ATE514700T1 (de) Neues tetrazyklisches heteroatom mit als sexualsteroidhormon-rezeptormodulatoren geeigneten derivaten
EA201391154A2 (ru) Способы и композиции для нацеливания на адипоциты у млекопитающих
PH12013500411A1 (en) Treatment of myocardial infarction using tgf - beta antagonists
EA201001749A1 (ru) Способ лечения недифференцированного артрита
BRPI0907220A2 (pt) métodos de tratar distúrbios de perda óssea usando um antagonista de gm-csf
EA201170447A1 (ru) Производные изохинолинона в качестве антагонистов nk3
EA201590522A1 (ru) Способы введения рифаксимина для снижения веса и лечения ожирения
EA201071146A1 (ru) Способы диагностирования, предупреждения и лечения болезней, связанных с костной массой
WO2009134725A3 (en) Monomethylamine progesteron antagonists such as cdb-4453 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc
MD20160066A2 (ru) Положительные аллостерические модуляторы никотинового рецептора ацетилхолина

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM